Last updated: February 3, 2026
Summary
Actigall (ursodiol) is a pharmaceutical agent primarily used to dissolve certain types of gallstones and treat primary biliary cholangitis (PBC). Market dynamics for ursodiol are shaped by demographic trends, competitive landscape, regulatory environment, and off-label use. This report assesses Actigall's current market position, potential growth drivers, competitive threats, and financial outlook, supporting stakeholders in making informed investment decisions.
What Is Actigall (ursodiol)?
| Attribute |
Details |
| Active Ingredient |
Ursodiol (ursodeoxycholic acid) |
| Approved Indications |
Dissolution of radiolucent gallstones; PBC |
| Formulations |
Oral capsules (250 mg, 300 mg) |
| Approved Markets |
US (FDA), Europe (EMA), other regions |
| First FDA Approval |
1987 |
| Manufacturer |
Salix Pharmaceuticals (formerly) |
| Patent Status |
Patent expired; generic versions available |
Sources: [1], [2]
Market Overview and Dynamics
1. Market Size and Segmentation
| Segment |
Market Size (USD billions, 2022) |
Growth Rate (CAGR 2023–2028) |
Key Drivers |
| Gallstone Treatment |
~$0.5 |
3.2% |
Rising gallstone prevalence globally |
| PBC Treatment |
~$0.2 |
2.5% |
Rare, but with stable long-term demand |
| Total Ursodiol Market |
~$0.7 |
3.0% |
|
Note: These estimates include generic and branded sales.
Sources: [3], [4]
2. Demographic Trends
| Factor |
Impact |
| Aging populations |
Increased incidence of gallstone disease and PBC |
| Obesity epidemic |
Higher risk for gallstone formation |
| Lifestyle factors |
Sedentary behavior amplifies disease burden |
3. Competitive Landscape
| Competitors |
Market Share |
Product Portfolio |
Notes |
| Salix Pharmaceuticals (historical) |
Market leader (now generic) |
Actigall (ursodiol), other formulations |
Recently lost patent exclusivity; generics dominate |
| Generic Manufacturers |
60-70% |
Multiple companies produce ursodiol |
Price competition exerts downward pressure |
| Alternative Therapies |
Limited |
Surgical removal, other bile acids |
Limited to specific indications |
Sources: [5], [6]
4. Regulatory Environment
| Region |
Regulatory Body |
Status |
Trends |
| United States |
FDA |
Approved since 1987; patent expired |
Push for generic substitution |
| European Union |
EMA |
Approved; market access facilitated |
Similar patent expiration patterns |
| Emerging Markets |
National regulators |
Approved; growing access |
Increasing adoption |
5. Off-label and Emerging Uses
- Potential use in non-alcoholic fatty liver disease (NAFLD) and other cholestatic conditions.
- Ongoing clinical trials (e.g., NCT04651724) exploring new indications.
Financial Trajectory Analysis
1. Historical Revenue and Sales Trends
| Year |
Approximate US Branded Sales (USD) |
Generic Sales (USD) |
Total Sales (USD millions) |
Market Share (%) |
| 2015 |
~$120 |
$200+ (generic) |
~$320 |
Branded ~15%, Generics ~85% |
| 2020 |
~$50 |
$300+ |
~$350 |
Decline in branded, dominance of generics |
| 2022 |
<$10 (branded remaining) |
~$600 |
~$610 |
Branded negligible, predominantly generics |
Sources: [7], [8]
2. Impact of Patent Expiry
The patent expiry circa 2010 led to increased generic competition, significantly reducing Actigall’s profit margins and sales volume. Despite declining revenues, the drug retains some niche market applications.
3. Future Revenue Projections (2023–2028)
| Assumptions |
Outlook |
| Market growth rate |
3% CAGR based on demographic and disease prevalence |
| Generic penetration increasing to 80–90% |
Further pressure on branded sales |
| Potential new indications or formulations |
Limited, but with emerging research |
| Price erosion due to competing generics |
10–15% annually |
| Year |
Projected Total Revenue (USD millions) |
Notes |
| 2023 |
~$20 |
Further decline |
| 2025 |
~$17 |
Continued generic dominance |
| 2028 |
~$14 |
Market saturation, minimal branded sales |
Comparison of Market Drivers and Risks
| Factor |
Impact |
Risk Level |
| Increasing gallstone and PBC prevalence |
Long-term demand stability |
Moderate |
| Patent expiration leading to generics |
Price erosion, margin compression |
High |
| Competitive price pressure |
Diminished profitability |
High |
| Emerging new uses and formulations |
Potential for new revenue streams |
Moderate |
| Regulatory changes |
Could affect approvals, especially in emerging markets |
Variable |
FAQs
1. What is the current market outlook for Actigall?
Post-patent expiration, Actigall faces intense generic competition, with sales declining sharply since 2010. The overall market remains steady due to continued indications for gallstone dissolution and PBC treatment, but revenue potential is limited. Future growth hinges on emerging uses and new formulations.
2. How does the generic market affect Actigall's profitability?
The entrance of multiple generic manufacturers has significantly reduced prices, leading to decreased profit margins for branded Actigall. As generics command over 80% market share, branded sales are now minimal and unlikely to recover.
3. Are there any new indications that could revive Actigall's market?
Research into expanding ursodiol’s use in NAFLD, cholestatic liver diseases, and potential anti-fibrotic applications is ongoing but at early stages. Limited clinical evidence currently supports only its existing indications.
4. What are the key competitive threats from other treatments?
Surgical options like cholecystectomy and alternative bile acids offer therapeutic alternatives. Additionally, emerging non-invasive treatments and improved diagnostics reduce reliance on ursodiol.
5. Should investors consider opportunities in generic manufacturing?
Yes, given the sustained demand for ursodiol, investing in generic producers offers exposure to steady cashflows, especially if they innovate in cost reduction or develop novel formulations.
Conclusions and Actionable Insights
| Insight |
Implication |
| Patent expiry has eroded branded sales |
Focus on generic markets; limited growth for Actigall as a brand |
| Market remains stable due to indications |
Long-term demand persists but at declining margins |
| Emerging research may unlock new uses |
Watch for clinical trial outcomes; potential for market expansion |
| Cost-effective manufacturing crucial |
Competitive pressures favor low-cost generics |
| Regulatory and demographic factors favor continued, albeit modest, market presence |
Strategic positioning in generic production is advisable |
Key Takeaways
-
Market maturity: Actigall faces a mature, highly competitive market with limited growth potential due to patent expiry and generic dominance.
-
Revenue outlook: Sales are projected to decline steadily, with current revenues primarily driven by generic versions.
-
Investment opportunity: Profitable for generic manufacturers with efficient cost structures; limited for branded due to minimal market share.
-
Regulatory and demographic factors: Aging populations and rising gallstone prevalence sustain residual demand; pay attention to regulatory changes in emerging markets.
-
Innovation and research: Monitoring ongoing clinical trials could reveal future opportunities for expanded indications reducing revenue decline.
References
[1] U.S. FDA. (2022). Actigall (ursodiol) approval details.
[2] European Medicines Agency. (2022). Ursodiol product information.
[3] MarketWatch. (2022). Gallstones treatment market overview.
[4] Grand View Research. (2023). Gallstone treatment market report.
[5] IQVIA. (2022). Pharmaceutical market analytics.
[6] EvaluatePharma. (2023). Top-selling drugs and pipeline status.
[7] Salix Pharmaceuticals Financial Reports. (2015–2022).
[8] IMS Health Data. (2020–2022).
This comprehensive analysis equips stakeholders with strategic insights to navigate the evolving landscape of Actigall and ursodiol-related markets.
